Compound (S)-4
(S)-3-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)-N-(2,3-dihydro-1H-inden-1-yl)propanamide
From: Expedited mapping of the ligandable proteome using fully functionalized enantiomeric probe pairs
View in PubChem | MDL Molfile | Chemdraw file
InChIKey GTYVBAWGEWLNHL-HNNXBMFYSA-N
Compound data: NMR
Synthetic procedure: See article for the definitive version of this procedure and for full experimental details.
The title compound was synthesised following the General Procedure outlined for compound (R)-1. The preparative TLC was run with n-hexane/ethyl acetate 3:1. 25.4 mg (90%) of the product were obtained. 1H NMR (500 MHz, Chloroform-d) δ 7.30 – 7.27 (m, 1H), 7.26 – 7.18 (m, 3H), 5.68 (d, J = 8.5 Hz, 1H), 5.46 (q, J = 7.7 Hz, 1H), 2.98 (m, 1H), 2.87 (dt, J = 16.1, 8.1 Hz, 1H), 2.59 (m, 1H), 2.03 (td, J = 7.5, 2.7 Hz, 2H), 1.99 – 1.93 (m, 3H), 1.92 – 1.87 (m, 2H), 1.81 (m, 1H), 1.67 (t, J = 7.5 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 170.81, 143.47, 142.96, 128.09, 126.82, 124.86, 124.03, 82.72, 77.30, 77.04, 76.79, 69.24, 54.78, 33.99, 32.46, 30.49, 30.23, 28.40, 27.89, 13.32. HRMS (m/z) calculated for C17H20N3O [M+H]+: 282.1601; found: 282.1601.
